Volume 2 Supplement 3
Turning tumor inhibition into activation: engineering T cells with chimeric signaling receptors
© Schlenker et al.; licensee BioMed Central Ltd. 2014
Published: 6 November 2014
Poor in vivo persistence and loss of function of adoptively transferred T cells in the tumor milieu are known shortcomings of adoptive T cell therapy (ATT). Providing costimulation might help to improve ATT efficiency. However, human CD8 T effector cells are largely CD28 negative and most tumors do not express CD80 or CD86, thus costimulation cannot be provided via CD28 ligation. We propose to facilitate costimulation of CD8 T effector cells in the tumor milieu through engineering of T cells with a chimeric signaling receptor, which can turn tumor mediated inhibition into activation by abrogating inhibitory PD1 signaling with concomitant activation of the costimulatory pathway. Human T cells engineered to express melanoma specific T cell receptors (TCR) plus the chimeric signaling molecule showed higher ERK phosphorylation associated with stronger IL-2 and IFN-γ secretion upon co-culture with PD-L1 positive target cells. T cells expressing a low avidity TCR achieved functional responses comparable to high avidity TCRs when engineered with the chimeric receptor. The chimeric receptor did not only increase cytokine secretion in vitro, but importantly, also supported intra-tumoral proliferation of T cells in a humanized mouse melanoma model.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.